GTPBP2 and neoplasm: We found fewer CD133+CD44+ cells (17.2%) in Gtpbp2−/− CCSC-derived tumor cells in comparison to Gtpbp2+/+ CCSC-derived tumor cells (22.6%) (Fig. 7C and D), suggesting weaker self-renewal of Gtpbp2−/− CCSCs.